HNO

, Volume 58, Issue 7, pp 713–725

Tumormarker und Prognosefaktoren bei Plattenepithelkarzinomen der Kopf-Hals-Region

  • G. Lehnerdt
  • T.K. Hoffmann
  • S. Mattheis
  • S. Brandau
  • R. Zeidler
  • S. Lang
CME Weiterbildung · Zertifizierte Fortbildung

Zusammenfassung

Mit den klassischen Prognosefaktoren für Kopf-Hals-Karzinome war eine Abschätzung des klinischen Verlaufs möglich, Unterschiede im individuellen Therapieansprechen oder im Verlauf stadiengleicher Tumoren blieben jedoch unscharf charakterisiert. Es mangelte an einer individuellen molekularen Signatur des einzelnen Tumors bzw. Patienten. Trotz zahlreicher Publikationen zu intensiv erforschten neuen Prognose-/Biomarkern orientieren sich die Therapieplanung und Prognoseabschätzung in den meisten Zentren mit wenigen Ausnahmen (z. B. HPV-Status bei Oropharynxkarzinomen) nur an den klassischen Parametern wie Tumorstadium und histologischem Differenzierungsgrad. Die Zukunft wird aber voraussichtlich nicht in Einzelmarkern, sondern in einem Markerprofil liegen, wie es die Microarray-Technologie ermöglicht. In dieser Arbeit werden die Kriterien für einen erfolgreichen Biomarkerkandidaten vermittelt und eine Übersicht über die wichtigsten neuen Biomarker gegeben. Zudem wird das Prinzip genomischer und proteomischer Biomarkerchips vorgestellt.

Schlüsselwörter

Tumormarker Biomarker HNSCC Kopf-Hals-Karzinome Prognose 

Diagnostic and prognostic biomarkers in head and neck squamous cell carcinoma

Abstract

Classical prognostic factors for squamous cell carcinoma of the head and neck (HNSCC) are based on general parameters such as tumor stage or histological grading and only allow for a rough estimation of the clinical course. However, predicting individual responses to treatment remains challenging and diverging clinical courses of same-stage HNSCC stage remain obscure. The need for a better understanding of the individual genomic or proteomic signature of HNSCC resulted in a great number of publications on novel biomarkers. Still, in most cancer centres therapy planning and risk appraisal are solely based on the classical factors with only a few exceptions such as HPV status in oropharyngeal carcinoma. Future improvements in biomarker research will probably be achieved with sets of various genomic and proteomic markers as provided by microarray technology. This review highlights the criteria for a successful biomarker candidate, gives an overview on the most important new biomarkers, and introduces the principles of genomic and proteomic biomarker chips.

Keywords

Tumormarker Biomarker HNSCC Head and neck carcinoma Prognosis 

Literatur

  1. 1.
    Bagnardi V, Blangiardo M, La VC, Corrao G (2001) A meta-analysis of alcohol drinking and cancer risk. Br J Cancer 85:1700–1705CrossRefPubMedGoogle Scholar
  2. 2.
    Begum S, Gillison ML, Ansari-Lari MA et al (2003) Detection of human papillomavirus in cervical lymph nodes: a highly effective strategy for localizing site of tumor origin. Clin Cancer Res 9:6469–6475PubMedGoogle Scholar
  3. 3.
    Bonner JA, Harari PM, Giralt J et al (2006) Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 354:567–578CrossRefPubMedGoogle Scholar
  4. 4.
    Chang SS, Califano J (2008) Current status of biomarkers in head and neck cancer. J Surg Oncol 97:640–643CrossRefPubMedGoogle Scholar
  5. 5.
    Chung CH, Parker JS, Karaca G et al (2004) Molecular classification of head and neck squamous cell carcinomas using patterns of gene expression. Cancer Cell 5:489–500CrossRefPubMedGoogle Scholar
  6. 6.
    Cojocariu OM, Huguet F, Lefevre M, Perie S (2009) Prognosis and predictive factors in head-and-neck cancers. Bull Cancer 96:369–378PubMedGoogle Scholar
  7. 7.
    Fakhry C, Westra WH, Li S et al (2008) Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial. J Natl Cancer Inst 100:261–269CrossRefPubMedGoogle Scholar
  8. 8.
    Geisler SA, Olshan AF, Weissler MC et al (2002) p16 and p53 Protein expression as prognostic indicators of survival and disease recurrence from head and neck cancer. Clin Cancer Res 8:3445–3453PubMedGoogle Scholar
  9. 9.
    Hoffmann TK, Whiteside TL, Bier H (2005) Plattenepithelkarzinome des Kopf-Hals-Bereichs – Grundlagen und aktuelle Konzepte der Immuntherapie. HNO 53: 285–298CrossRefPubMedGoogle Scholar
  10. 10.
    Hsu KF, Hung CF, Cheng WF et al (2001) Enhancement of suicidal DNA vaccine potency by linking mycobacterium tuberculosis heat shock protein 70 to an antigen. Gene Ther 8:376–383CrossRefPubMedGoogle Scholar
  11. 11.
    Kornberg LJ, Villaret D, Popp M et al (2005) Gene expression profiling in squamous cell carcinoma of the oral cavity shows abnormalities in several signaling pathways. Laryngoscope 115:690–698PubMedGoogle Scholar
  12. 12.
    Lang S, Zeidler R (2003) Immune restoration in head and neck cancer patients via cyclooxygenase inhibition: an update. Int J Immunopathol Pharmacol 16:41–48PubMedGoogle Scholar
  13. 13.
    Langendijk JA, Slotman BJ, van der Waal I et al (2005) Risk-group definition by recursive partitioning analysis of patients with squamous cell head and neck carcinoma treated with surgery and postoperative radiotherapy. Cancer 104:1408–1417CrossRefPubMedGoogle Scholar
  14. 14.
    Lehnerdt GF, Franz P, Zaqoul A et al (2008) Overall and relapse-free survival in oropharyngeal and hypopharyngeal squamous cell carcinoma are associated with genotypes of T393C polymorphism of the GNAS1 gene. Clin Cancer Res 14:1753–1758CrossRefPubMedGoogle Scholar
  15. 15.
    Pai SI, Westra WH (2009) Molecular pathology of head and neck cancer: implications for diagnosis, prognosis, and treatment. Annu Rev Pathol 4:49–70CrossRefPubMedGoogle Scholar
  16. 16.
    Pelucchi C, Gallus S, Garavello W et al (2008) Alcohol and tobacco use, and cancer risk for upper aerodigestive tract and liver. Eur J Cancer Prev 17:340–344CrossRefPubMedGoogle Scholar
  17. 17.
    Poeta ML, Manola J, Goldwasser MA et al (2007) TP53 mutations and survival in squamous-cell carcinoma of the head and neck. N Engl J Med 357:2552–2561CrossRefPubMedGoogle Scholar
  18. 18.
    Ranelletti FO, Almadori G, Rocca B et al (2001) Prognostic significance of cyclooxygenase-2 in laryngeal squamous cell carcinoma. Int J Cancer 95:343–349CrossRefPubMedGoogle Scholar
  19. 19.
    Rocco JW, Li D, Liggett WH Jr et al (1998) p16INK4A adenovirus-mediated gene therapy for human head and neck squamous cell cancer. Clin Cancer Res 4:1697–1704PubMedGoogle Scholar
  20. 20.
    Scurry WC Jr, Stack BC Jr (2007) Role of metalloproteins in the clinical management of head and neck squamous cell carcinoma. Head Neck 29:1144–1155CrossRefPubMedGoogle Scholar
  21. 21.
    Silva P, Homer JJ, Slevin NJ et al (2007) Clinical and biological factors affecting response to radiotherapy in patients with head and neck cancer: a review. Clin Otolaryngol 32:337–345PubMedGoogle Scholar
  22. 22.
    Thomas GR, Nadiminti H, Regalado J (2005) Molecular predictors of clinical outcome in patients with head and neck squamous cell carcinoma. Int J Exp Pathol 86:347–363CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag 2010

Authors and Affiliations

  • G. Lehnerdt
    • 1
  • T.K. Hoffmann
    • 1
  • S. Mattheis
    • 1
  • S. Brandau
    • 1
  • R. Zeidler
    • 2
  • S. Lang
    • 1
  1. 1.Universitäts-Hals-Nasen-Ohren-Klinik, Universitätsklinikum EssenEssenDeutschland
  2. 2.Universitäts-Hals-Nasen-Ohren-Klinik, Klinikum der Universität MünchenMünchenDeutschland

Personalised recommendations